Roth/MKM Starts CervoMed (CRVO) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall St futures slide as rising oil, yields dampen mood
- Oil jumps as Middle East supply concerns persist amid shipping attacks
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
- Wall Street ends lower, off record highs, as Treasury yields climb
- Applied Digital (APLD) Tops Q1 EPS by 26c, Beats on Revenue
H.C. Wainwright Starts CervoMed (CRVO) at Buy
December 5, 2024 6:05 AM ESTH.C. Wainwright analyst Raghuram Selvaraju initiates coverage on CervoMed (NASDAQ: CRVO) with a Buy rating and a price target of $42.00.
For an analyst ratings summary and ratings history on CervoMed click here. For more ratings news on CervoMed click here.
Shares of CervoMed closed at $9.70 yesterday.
... More


